ORYZON Selected as one of the Finalist for the 7th Annual Most Innovative EU Biotech SME Award

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (Madrid Stock Exchange: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today it has been selected as one of the 7 finalists by the European Association for Bioindustries (EuropaBio) for its Most Innovative European Biotech SME Awards. The other finalists nominated to this award include: Cellectis, TiGenix, OxyMem, MetGen, Biosyntia, and Plant Response Biotech. This year, 41 companies from 13 different European countries applied for this award.

Click here to see the full Press Release